ClinicalTrials.gg
Not yet recruitingNCT06911775IREOSUpdated Apr 4, 2025

Eosinophil Subpopulations in Eosinophilic-associated Diseases

An observational study in Eosinophilic Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES), sponsored by University of Florence. Not yet recruiting. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by University of Florence · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
160
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This single-center, non-commercial study will involve 160 participants (80 with eosinophilic asthma (EA), 30 with eosinophilic granulomatosis with polyangiitis (EGPA), 25 with hypereosinophilic syndrome (HES), and 25 healthy donors) to investigate eosinophil subpopulations in these diseases. The study will run from Q4 2024 to Q4 2026.

Objectives:

Primary: To verify two eosinophil subpopulations (iEos and rEos) in EGPA and HES and analyze the role of type 2 cytokines on their plasticity.

Secondary: Compare iEos proportion between different eosinophilic diseases and correlate with disease severity.

Exploratory: Assess the effect of mepolizumab on eosinophil subpopulations in vitro.

Population: Adults aged 18-75 with EA, EGPA, or HES, and healthy controls. EA patients must have >300 eosinophils/mcL, EGPA requires asthma + eosinophilia + other specific features, and HES requires high eosinophil counts (>1500 cells/mL).

Methods: Data will be analyzed using Mann-Whitney U, ANOVA, and Spearman correlation tests, with results presented as mean ± SEM.

This study will help explore eosinophil behavior in eosinophilic diseases and evaluate mepolizumab's effects on these cells.

Read the detailed description

Introduction Eosinophils (Eos) play a crucial role in both normal physiological functions and various pathological conditions. They are primarily recognized for their involvement in immune defense against infections, including parasitic, bacterial, and viral infections, as well as in cancer surveillance. However, they are also key contributors to eosinophil-associated diseases (EADs) such as bronchial asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES).

Recent research has revealed that eosinophils exist in distinct subpopulations with unique phenotypic characteristics and functions. These subpopulations, referred to as resident eosinophils (rEos) and inflammatory eosinophils (iEos), have been primarily studied in healthy tissues and in conditions like severe eosinophilic asthma (SEA) and CRSwNP. While rEos are believed to contribute to tissue homeostasis and immune regulation, iEos are associated with inflammatory responses. Studies in mouse models have demonstrated the presence of these subpopulations in lung tissue, but their role in human disease remains less understood.

Although there is emerging evidence suggesting the presence of these eosinophil subsets in human peripheral blood and nasal polyp tissue, they have not been fully characterized in other EADs such as EGPA and HES. Understanding whether these subpopulations exist in these diseases and how they are influenced by type 2 cytokines could provide valuable insights into disease mechanisms. Furthermore, as eosinophil-targeted therapies such as Mepolizumab (an anti-IL-5 monoclonal antibody) are already in clinical use, clarifying their specific effects on these eosinophil subsets could help optimize treatment strategies.

Study Rationale and Objectives This study aims to expand on previous findings by investigating whether distinct eosinophil subpopulations exist in EGPA and HES patients. Additionally, the study seeks to analyze how type 2 cytokines influence the differentiation and function of these eosinophil subsets. A key aspect of this research is assessing the effect of Mepolizumab on rEos and iEos, particularly whether it selectively targets inflammatory eosinophils without affecting homeostatic eosinophils.

The primary objectives of this study include:

Confirming the presence of two distinct eosinophil subpopulations in EGPA and HES.

Investigating the impact of type 2 cytokines on eosinophil plasticity and function.

Secondary objectives involve comparing iEos proportions across different eosinophilic diseases and analyzing their correlation with disease severity. Additionally, the study will explore how in vitro exposure to Mepolizumab affects the balance between rEos and iEos in EGPA and HES patients.

Study Design The study will involve patients diagnosed with severe eosinophilic asthma (SEA), EGPA, and HES, along with a control group of healthy donors. Blood samples will be collected and analyzed using flow cytometry to characterize eosinophil subpopulations. In vitro experiments will assess the effects of type 2 cytokines (such as IL-5, IL-3, GM-CSF, IL-4, and IL-13) on these eosinophil subsets, as well as the impact of Mepolizumab.

Subject Selection and Eligibility Criteria Participants must be between 18 and 75 years old and diagnosed with SEA, EGPA, or HES. Healthy donors within the same age range will be included as controls. Individuals with chronic lung diseases (such as COPD), other immune-mediated inflammatory conditions, recent infections, parasitic infestations, or immunosuppressive treatments will be excluded to ensure a clear focus on eosinophilic-driven inflammation.

Ethical Considerations and Study Management This study will adhere to ethical guidelines outlined in the Declaration of Helsinki and Good Clinical Practice (GCP) regulations. Informed consent will be obtained from all participants, ensuring they fully understand the study's purpose and procedures. Ethical approval will be secured from the relevant institutional review boards before the study commences.

Biological samples will not be stored beyond their immediate use, and strict chain-of-custody procedures will be followed. If a participant withdraws consent, their samples will be immediately destroyed unless they have already been analyzed.

Statistical Analysis and Expected Outcomes This is an exploratory pilot study, and an estimated 135 patients (80 SEA, 30 EGPA, 25 HES) and 25 healthy donors will be recruited. Statistical methods, including Mann-Whitney U tests, ANOVA, and Spearman correlation tests, will be used to analyze the data. The primary focus will be to determine the proportion of iEos and rEos in different disease states and evaluate their response to cytokine stimulation and Mepolizumab treatment.

If successful, this study could lead to a deeper understanding of eosinophil biology and its implications in eosinophilic disorders. More importantly, it could refine therapeutic strategies by identifying whether Mepolizumab specifically targets inflammatory eosinophils while preserving homeostatic ones, ultimately leading to more personalized treatment approaches for patients with EADs.

02

Conditions studied

  • Eosinophilic Asthma
  • Eosinophilic Granulomatosis With Polyangiitis (EGPA)
  • Hypereosinophilic Syndrome (HES)

Keywords

  • Eosinophils
  • EGPA
  • HES
  • EA
  • Eosinophilic asthma
  • Eosinophil subpopulations
  • Flowcytometry
  • Biomarker
  • Asthma severity
  • EGPA severity
03

In context

Churg-Strauss Syndrome

61 studies on the registry are indexed under Churg-Strauss Syndrome; 17 are open to participants now.

This study's planned enrollment of 160 is below the median of 239 across 30 observational studies indexed under Churg-Strauss Syndrome.

Browse Churg-Strauss Syndrome studies →

Lead sponsor

University of Florence is the lead sponsor of 76 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Each subject should meet all of the inclusion criteria and none of the exclusion criteria for this study. Under no circumstances can there be exceptions to this rule.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For inclusion in the study subjects should fulfill the following criteria based on local regulations:

Patients with Asthma, or EGPA or HES:

  1. Age between 18 and 75 years at the time of signing the
  2. Patients with EA, EGPA or HES
  3. Provision of signed and dated written informed consent form prior to any mandatory study procedures, sampling and analysis.

Healthy donors:

  1. Age between18 and 75 years healthy donors

Exclusion criteria

Exclusion Criteria:

  • Subjects should not enter the study if any of the following exclusion criteria are fulfilled:

    1. Presence of other chronic pulmonary diseases including
    2. Presence of other chronic immuno-mediated inflammatory diseases
    3. Treatment with oral prednisone or equivalent > 7.5 mg/day
    4. Treatment with long-acting depot in the last three months
    5. Use of medications (cyclosporine A; azathioprine; methotrexate; mycophenolate mofetil)
    6. Receipt of 30 days prior to the enrollment
    7. Acute upper or lower respiratory infections within 30 days prior to the date is obtained or during the screening/run-in period.
    8. A helminth parasitic infection diagnosed within 24 weeks prior to the date informed consent is obtained that has not been treated with, or has failed to respond to, standard of care therapy
    9. Subjects who are pregnant or breastfeeding
    10. Current smoking
    11. Any abnormal findings in physical examination, vital signs, hematology, or clinical chemistry during screening period, which in the opinion of the investigator may put the patient at risk of his/her participation in the study, or may influence the results of the study, or the patient\'s ability to complete entire duration of the study.
    12. Concurrent enrolment in another interventional or post-authorization safety study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
160 participants (estimated)
Patient registry
No

Groups and cohorts

  • Healthy donors

    25 healthy subject

  • EA

    80 eosinophilic asthma patients

  • EGPA

    30 EGPA patients

  • HES

    25 HES patients

06

What researchers measure

Primary outcomes

  1. Primary objective: first outcome measure

    1) Proportion of circulating Siglec8+CD16-CD62Llow (iEos) and Siglec8+CD16-CD62Lbright (rEos) cells in bio- naïve, EGPA and HES patients

    Time frame: From the enrollment of the first patient at 20 months

  2. Primary objective: second outcome measure

    2) Modification of the expression of CD62L on peripheral eosinophils upon in vitro stimulation with IL-5, IL-3, GM-CSF, IL-4, IL-13

    Time frame: From the enrollment of the first patient at 20 months

Secondary outcomes

  1. Secondary objective: first outcome measure

    1) Proportion of circulating Siglec8+CD16-CD62Llow (iEos) cells in bio-naïve EA, EGPA, and HES patients

    Time frame: From the enrollment of the first patient at 18 months

  2. Secondary objective: second outcome measure

    2) Correlation between Siglec8+CD16-CD62Llow (iEos) cells and disease-specific clinical scores in bio-naïve EGPA, HES and EA patients

    Time frame: From the enrollment of the first patient at 18 months

Other outcomes

  1. Explorative objective

    1) Modification of the proportion of CD62Llow and CD62Lbright among eosinophils obtained from EGPA and HES patients, upon in vitro coculture with mepolizumab and type 2 cytokines.

    Time frame: From month 7 to month 20

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Matucci A, Nencini F, Maggiore G, Chiccoli F, Accinno M, Vivarelli E, Bruno C, Locatello LG, Palomba A, Nucci E, Mecheri V, Perlato M, Rossi O, Parronchi P, Maggi E, Gallo O, Vultaggio A. High proportion of inflammatory CD62Llow eosinophils in blood and nasal polyps of severe asthma patients. Clin Exp Allergy. 2023 Jan;53(1):78-87. doi: 10.1111/cea.14153. Epub 2022 May 4. PubMed 35490414 ↗
  • Januskevicius A, Jurkeviciute E, Janulaityte I, Kalinauskaite-Zukauske V, Miliauskas S, Malakauskas K. Blood Eosinophils Subtypes and Their Survivability in Asthma Patients. Cells. 2020 May 18;9(5):1248. doi: 10.3390/cells9051248. PubMed 32443594 ↗
  • Xenakis JJ, Howard ED, Smith KM, Olbrich CL, Huang Y, Anketell D, Maldonado S, Cornwell EW, Spencer LA. Resident intestinal eosinophils constitutively express antigen presentation markers and include two phenotypically distinct subsets of eosinophils. Immunology. 2018 Jun;154(2):298-308. doi: 10.1111/imm.12885. Epub 2018 Jan 21. PubMed 29281125 ↗
  • Marichal T, Mesnil C, Bureau F. Homeostatic Eosinophils: Characteristics and Functions. Front Med (Lausanne). 2017 Jul 11;4:101. doi: 10.3389/fmed.2017.00101. eCollection 2017. PubMed 28744457 ↗
  • Mesnil C, Raulier S, Paulissen G, Xiao X, Birrell MA, Pirottin D, Janss T, Starkl P, Ramery E, Henket M, Schleich FN, Radermecker M, Thielemans K, Gillet L, Thiry M, Belvisi MG, Louis R, Desmet C, Marichal T, Bureau F. Lung-resident eosinophils represent a distinct regulatory eosinophil subset. J Clin Invest. 2016 Sep 1;126(9):3279-95. doi: 10.1172/JCI85664. Epub 2016 Aug 22. PubMed 27548519 ↗
  • Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol. 2013 Jan;13(1):9-22. doi: 10.1038/nri3341. Epub 2012 Nov 16. PubMed 23154224 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2025; primary completion for Jul 2026, 15 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2025
First posted
Apr 4, 2025
StartEst.
Apr 2025
Primary completionEst.
Jul 2026
CompletionEst.
Dec 2026
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06911775
Lead sponsor
University of Florence
Collaborators
GlaxoSmithKline
Responsible party
Alessandra Vultaggio (Principal investigator, researcher, University of Florence) — Principal investigator
First posted
Apr 4, 2025
Start date
Apr 2025 (estimated)
Primary completion
Jul 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion